EHD2 Antibody Nuclear Localization Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current EHD2 antibodies lack specificity and are not suitable for immunohistochemical detection, particularly for nuclear localization of EHD2 protein in clinical tissue samples, which is crucial for diagnosing and prognosing cancer.
Innovation Solution
A synthetic peptide-based antibody specific to human EHD2 protein is developed, using a 42-amino-acid fragment of the EHD2 protein sequence with a cysteine at the N-terminal, coupled with an antigen carrier, and subjected to affinity purification for immunohistochemical detection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional antibodies are used for EHD2 detection, then detection can be performed, but the antibodies lack specificity and cannot detect nuclear localization of EHD2 protein
Solution Approach 1:
The patent segments the EHD2 protein into a specific 42-amino-acid fragment (residues 503-543) to generate a highly specific antibody. This segmentation allows the antibody to target a precise epitope region, thereby achieving high detection specificity for nuclear EHD2 localization while maintaining reliability for immunohistochemical applications.
Solution Approach 2:
The patent applies local quality by focusing the antibody recognition on a specific nuclear-localized epitope of EHD2 (amino acids 503-543). This localized targeting ensures the antibody specifically detects nuclear EHD2 protein, resolving the issue of non-specific detection and enabling reliable immunohistochemical analysis of nuclear localization.
2Measurement precision
If morphology-based diagnosis is used, then tumor differentiation can be assessed, but accuracy is limited by human factors and lacks molecular level evidence
Solution Approach 1:
The patent introduces a specific antibody as an intermediary tool that bridges morphology-based diagnosis and molecular-level detection. The antibody enables immunohistochemical detection of EHD2 protein expression and nuclear localization, providing objective molecular evidence that complements morphological assessment and improves diagnostic accuracy without requiring complex molecular biology techniques.
3Reliability
If EHD2 protein expression is detected to understand tumor malignancy, then molecular characteristics can be clarified, but existing antibodies cannot specifically detect nuclear EHD2 localization
Solution Approach 1:
The patent performs preliminary action by designing and synthesizing a specific peptide antigen (amino acids 503-543 of EHD2) before antibody generation. This pre-selected epitope is known to be nuclear-localized, ensuring that the resulting antibody will specifically detect nuclear EHD2 protein, thereby achieving both reliable molecular marker detection and precise nuclear localization identification.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibody effectively detects and quantifies nuclear EHD2 protein expression, correlating with cancer malignancy and patient survival, providing a reliable method for breast cancer diagnosis and prognosis.
Implementation Method 1
Through specific recognition of antibodies to protein antigens in the body plus color development of secondary antibodies with chemical labelling
Implementation Method 2
color development of secondary antibodies with chemical labelling (fluorophore, enzyme, metal ion, isotope and etc.)
Data Source
AI summary
The present application provides a synthetic peptide with an amino acid sequence SEQ ID NO: 1 plus a cysteine at its N-terminal, an artificial antigen, an antibody specific to a human EHD2, a method for preparing an antibody specific to the human EHD2 protein and adopted to an immunohistochemical method for EHD2 detection as well as cancer diagnosing and prognosing.